Citations

Clear

941 citation(s) found for "Tan, MH".

Sex‐related differences in the trends and outcomes of trans‐septal transcatheter mitral valve replacement: Insights from the National Readmissions Database
Elbadawi, Ayman , Tan, Bryan E‐Xin , Saad, Marwan , Sharaf, Barry L., Gordon, Paul , Saad, Marwan , Tan, Bryan E-Xin , Sammour, Yasser M. , Omer, Mohamed , Baron, Suzanne J. , Abbott, J. Dawn

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 8, 2022 | Volume: 99 | Issue: 5 | Pages: 1636-1644

10.1002/ccd.30072 | PMID 35132765 Get It

AbstractBackgroundThere is a paucity of data regarding the sex‐related differences in the trends and outcomes of trans‐septal transcatheter mitral valve replacement (TS‐TMVR).MethodsThe Nationwide Readmissions Database (2015–2018) was queried for admissions for TS‐TMVR. Propensity matched analysis was conducted to compare outcomes with hospitalizations for TS‐TMVR among women versus men. The main study outcome was in‐hospital mortality.ResultsOur final analysis included 2063 hospitalizations for TS‐TMVR; of whom, 58.1% were women. The proportion of women among those undergoing TS‐TMVR increased from 50% in 2015 to 60.2% in 2018 (Ptrend = 0.04). Compared with men, women undergoing TS‐TMVR were slightly younger, and had a distinct profile of comorbidities. After matching, there was no significant difference in in‐hospital mortality among women versus men undergoing TS‐TMVR (7.8% vs. 6.1%, OR = 1.30; 95% CI: 0.79–2.13). Subgroup analyzes showed an interaction toward higher mortality with women versus men among patients with CKD (Pinteraction = 0.07). There were no significant differences between women and men in in‐hospital complications or length of stay after TS‐TMVR. Compared with men, women undergoing TS‐TMVR were more likely to be discharged to a nursing facility (17.7% vs. 11.5%, p = 0.01) and had higher rates of 30‐day readmissions (22.4% vs. 13.6%, p = 0.01).ConclusionThis nationwide analysis showed an increase in the proportion of women among patients undergoing TS‐TMVR during the study years. There were no differences in in‐hospital mortality, in‐hospital complications, or length of stay between both sexes following TS‐TMVR. Women were more likely to be discharged to nursing facilities and had higher rates of readmission at 30 days even after propensity matching.
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration
Banga, Yasmin B, Lai, Yujung, Kim, Priscilla , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Brushaber, Danielle , Bordelon, Yvette , Dickerson, Brad C., Dickinson, Susan, Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fishman, Ann, Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kornak, John , Lagone, Emma, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Manoochehri, Masood , Masdeu, Joseph C. , McGinnis, Scott, Mendez, Mario F, Miyagawa, Toji , Nelson, K. , Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Sabbagh, Marwan N. , Salmon, David P. , Savica, Rodolfo , Staffaroni, Adam M. , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Jack C. , Weıntraub, Sandra , Wheaton, Diana, Wong, Benjamin , Boeve, Bradley F. , Appleby, Brian S. , Biernacka, Joanna M. , Botha, Hugo , Bozoki, Andrea C , Brannelly, Patrick , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Gendron, Tania F. , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F, Miller, Bruce L. , Nelson, Kevin M, Pascual, Belén , Pottier, Cyril , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052495 Get It

AbstractBackgroundFrontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative conditions, affecting the frontal and/or temporal lobes. Ongoing research has provided insight into developing clinical trials for FTLD and key clinical measures such as structural MRI. To inform clinical trial design and optimize participation, it is imperative to explore facilitators and barriers for potential candidates.ObjectiveThe objective of this study is to explore facilitators and barriers to participating in future clinical trials for FTLD.MethodsAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) are observational studies focused on characterizing FTLD syndromes in preparation for clinical trials. The 584 participants enrolled across 18 research sites in the United States and Canada completed a survey assessing interest in clinical trial participation.Results29% of respondents self‐reported as patients (63±10 years), 26% self‐reported as caregivers answering on behalf of patients (65±10 years), and 45% self‐reported as healthy but at risk for FTLD (48±14 years). Travel reimbursement was the most common factor reported to positively influence participation (≧66%), with the healthy but at risk group showing the strongest endorsement (83%). Cost and time involved in travel were possible barriers for about half of the patients (48%) and healthy but at risk respondents (53%). The respondents value receiving feedback on the study findings (≧80%) and being informed of their individual disease progression (≧75%). Particularly, keeping participation confidential was very important for the healthy but at risk group (62%). In regard to research assessments, most participants demonstrated a high interest in physical and neurological exams at a research center (≧87%) whereas only half were interested in doing more invasive procedures such as the lumbar puncture (≧52%). Overall, respondents showed a positive attitude and support for research participation (≧77%) and trusted that their health information would remain confidential in a clinical trial (≧53%).ConclusionsFavorable attitudes and interest towards medical research exist among participants. To optimize participation, clinical trials should allocate funding for travel and involve participants in feedback about study results and their disease progression. Alternatives to invasive assessments may increase participation.
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Biliary tract cancer cohort.
Ramos, Jorge , Tan, Qianwen, Bekaii‐Saab, Tanios , Nakamura, Yoshiaki

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: TPS489-TPS489

10.1200/jco.2022.40.4_suppl.tps489 Get It

TPS489 Background: Tucatinib (TUC), a highly selective HER2-directed TKI approved in multiple regions for HER2+ metastatic breast cancer, is being investigated as a novel therapy for patients (pts) with metastatic colorectal cancer, gastric cancer, and other GI tumors. Preclinical and clinical data have shown HER2-targeted agents may improve clinical outcomes. In xenograft models of HER2+ and HER2-mutated tumors, dual targeting of HER2 with TUC + trastuzumab (Tras) showed superior activity to either agent alone (Kulukian 2020). Interim results from the MOUNTAINEER study have shown promising activity for TUC + Tras in HER2+ colorectal cancer. In 23 response-evaluable pts, an objective response rate (ORR) of 52% was observed with a median progression-free survival (PFS) of 8.1 months (mo) (Strickler 2019). The prognosis for pts with biliary tract cancers (BTCs) remain poor, and treatment options are limited. Given that approximately 12%-15% of BTC pts are HER2+, and 1%-8% have HER2 mutations, TUC + Tras warrants further evaluation in this patient population. The SGNTUC-019 basket study (NCT04579380) is evaluating TUC + Tras in pts with previously treated, locally advanced, unresectable or metastatic solid tumors including BTC that display HER2 overexpression/amplification or activating mutations. We describe the design of the BTC cohort. Methods: SGNTUC-019 is a multi-cohort, open-label, international Phase 2 study. Pts must be ≥18 years old; have an ECOG PS of ≤1; have adequate hepatic, hematological, renal, and cardiac functions; and have no previous exposure to HER2-directed therapy. BTC pts must have progressed on or after ≥1 previous line of treatment. The HER2+ BTC cohort will enroll 12 response-evaluable pts. If >2 responses are observed, the cohort will be expanded to 30 pts. HER2-mutated BTC patients may also be enrolled in a 30 pts cohort for other HER2-mutated solid tumors. The primary objective is antitumor activity with confirmed ORR as the primary endpoint. Secondary efficacy endpoints include disease control rate, duration of response, PFS, and OS. For eligibility, HER2 alterations can be demonstrated by HER2 overexpression/amplification in tumor tissue by prior IHC/ISH, or by HER2 amplification/mutation in a prior or on-study NGS assay of ctDNA or prior tissue NGS assay. Pts will receive TUC 300 mg orally twice a day and Tras 8 mg/kg intravenously on Cycle 1 Day 1 then 6 mg/kg every 21 days from Cycle 2 Day 1. Disease assessments per RECIST 1.1 are every 6 weeks for the first 24 weeks, then every 12 weeks. Quality of life will be evaluated every 2 cycles using EQ-5D-5L. Sites are currently enrolling within the US, EU and Asia-Pacific. Clinical trial information: NCT04579380.
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in p
Park, Haeseong , Kim, Sunnie S., Pishvaian, Michael J. , Mayor, JoAl, Tan, Qianwen, Bekaii‐Saab, Tanios , Kamath, Suneel Deepak , Chen, Christopher S. , Zhen, David B. , Strickler, John H.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: TPS376-TPS376

10.1200/jco.2022.40.4_suppl.tps376 Get It

TPS376 Background: Human epidermal growth factor receptor 2 ( HER2) gene amplification or protein overexpression (HER2+) occurs in many gastrointestinal (GI) cancers; thus, there is interest in evaluating HER2-targeted therapies in these tumor types. Tucatinib (TUC) is a highly selective HER2-directed tyrosine kinase inhibitor with minimal EGFR inhibition, approved in multiple regions for HER2+ metastatic breast cancer. In patient-derived xenograft models of HER2+ tumors (including esophageal, gastric, and colorectal cancers), TUC + trastuzumab showed superior anti-tumor activity compared with either agent alone (Kulukian 2020). In the MOUNTAINEER study, TUC + trastuzumab in HER2+ metastatic colorectal cancer (CRC) resulted in an objective response rate of 52% and a median duration of response of 10.4 months (interim results, Strickler 2019). The SGNTUC-024 study (NCT04430738) will evaluate TUC + trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic GI cancers. Methods: SGNTUC-024 is an open-label, dose escalation and expansion phase 1b/2 trial. Phase 1b assesses the safety and tolerability of TUC + trastuzumab + either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) with or without pembrolizumab. One chemotherapy-free cohort is planned (TUC + trastuzumab + pembrolizumab). The initial phase 1b cohort enrolled patients with gastric, esophageal, and gastroesophageal junction (GEJ) adenocarcinomas; cholangiocarcinoma; gallbladder carcinoma; and CRC to receive TUC (150 mg oral [PO] twice daily [BID]) + trastuzumab + FOLFOX. Subsequent phase 1b cohorts will receive TUC (300 mg PO BID) + trastuzumab + either FOLFOX or CAPOX. Once the recommended dose for use with oxaliplatin is identified, cohorts enrolling patients with gastric, esophageal, and GEJ adenocarcinomas will open with patients receiving TUC (300 mg PO BID) + trastuzumab + pembrolizumab with or without either FOLFOX or CAPOX. Phase 2 will expand the assessment of safety and efficacy and enroll 2 cohorts: patients with gastric, esophageal, and GEJ adenocarcinomas (to receive TUC + trastuzumab + pembrolizumab + either FOLFOX or CAPOX, Cohort A) and patients with CRC (to receive TUC + trastuzumab + FOLFOX, Cohort B). Safety and efficacy will be summarized with descriptive statistics. Patients that receive chemotherapy must be eligible for an oxaliplatin-based regimen as standard of care. Patients with irradiated or resected central nervous system (CNS) lesions may enroll, and patients with known active CNS lesions may be eligible for phase 2. The phase 1b portion of the trial is currently enrolling. Clinical trial information: NCT04430738.
Core homologous recombination mutations and improved survival in nonpancreatic GI cancers.
Tan, Elaine , Whiting, Junmin , Walko, Christine M. , Imanirad, Iman , Carballido, Estrella M., Felder, Seth , Frakes, Jessica M. , Anaya, Daniel A. , Fleming, Jason B. , Knepper, Todd C. , Xie, Hao , Mo, Qianxing , Permuth, Jennifer B. , Kim, Richard D. , Şahin, İbrahim Halil

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 663-663

10.1200/jco.2022.40.4_suppl.663 Get It

663 Background: GI malignancies continue to be a major cause of cancer related deaths, despite advances in therapy options. In pancreatic cancer, the presence of homologous recombination mutations (HRM) has been shown to confer increased sensitivity to platinum chemotherapy. However, the role of HRM mutations in other GI cancers remains to be determined. The focus of this study is to evaluate the prognostic nature of core and noncore HRM in nonpancreatic GI cancers. Additionally, we aim to understand the predictive nature of these mutations related to platinum exposure. Methods: This was a retrospective review of patients at Moffitt Cancer Center with a primary stage IV nonpancreatic GI cancer treated with platinum therapy. All patients had next generation sequencing and were in the Clinical Genomics Action Committee database between 1/1/2013 and 11/1/2020. All patients had either a core HRM (BRCA1, BRCA2, PALB2) or noncore HRM (such as ATM, ATR, BARD1, BRIP1, FANCA, NBN, and RAD51). Patients were grouped into core HRM vs. noncore HRM. Response was stratified between responders (complete response and partial response) vs. non responders (stable disease and progressive disease), based on RECIST criteria. Progression free survival and overall survival were estimated using Kaplan-Meier method, and the log-rank test was used to assess the difference in progression free survival (PFS) and overall survival (OS) by HRM status and type of platinum therapy used. Results: There were 72 patients included in the study: the majority of patients were male (65.3%) and Caucasian (87.5%). Twenty-one (29.2%) patients had a core HRM and 51 (70.8%) had a noncore HRM. There was no significant difference in response rate between patients with core HRM and patients with noncore HRM for evaluable patients (n = 66): 20.0% of patients with core HRM vs. 21.7% of patients with noncore HRM demonstrated a response to platinum therapy (p = 0.41). An improved OS was noted for patients with core HRM vs. those with noncore HRM at 68.9 vs. 24.3 months (p = 0.019). An improved PFS was also seen in patients with core HRM at 10.4 months vs. 6.3 months with noncore HRM (p = 0.027). There was no difference in PFS based on type of platinum therapy used (oxaliplatin vs. carboplatin vs. cisplatin), while an improved OS was noted for patients treated with oxaliplatin vs. carboplatin vs. cisplatin at 43.1 vs. 28.2 vs. 16.0 months (p = 0.011). Conclusions: Our study demonstrated that in stage IV nonpancreatic GI malignancies treated with platinum therapy, patients with core HRM had a greater OS and PFS compared to those with noncore HRM, suggesting a potential prognostic and predictive role of these mutations. Further studies are needed to confirm our findings.
Association of BRAF V600E mutation with survival in patients with metastatic mismatch repair-deficient colorectal cancer.
Tan, Elaine , Whiting, Junmin , Imanirad, Iman , Carballido, Estrella M., Felder, Seth , Frakes, Jessica M. , Walko, Christine M. , Anaya, Daniel A. , Fleming, Jason B. , Xie, Hao , Mo, Qianxing , Permuth, Jennifer B. , Kim, Richard D. , Şahin, İbrahim Halil

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 174-174

10.1200/jco.2022.40.4_suppl.174 Get It

174 Background: Colorectal cancer (CRC), while one of the most common cancer diagnoses, can behave heterogeneously based on molecular characteristics. A subset of patients (pts) with CRC are characterized with mismatch repair deficiency (MMR-d), these pts exhibit encouraging responses to immunotherapy. The predictive nature of various factors, such as BRAF status, age, and MMR-D protein loss type, have been investigated in pts with MMR-d CRC. However, the prognostic role of these factors has not been well established. The purpose of this study was to identify characteristics that influence survival in MMR-d mCRC. Methods: This study evaluated pts with MMR-d mCRC in the Flatiron database. Overall survival (OS) was determined from date of diagnosis of stage IV disease to date of death and stratified based on age greater than or less than 50 years, BRAF mutation status, RAS mutation status, and type of MMR gene loss. For statistical analysis, the Chi-Square test was implemented to determine the prognostic significance of clinical and molecular features. Univariate and multivariate analyses were determined through the Cox regression model. Results: There were 1,101 pts in the study. The majority of pts were older than 50 (79.7%), Caucasian (75%), and had ECOG 0-1 (83.4%). Among the 803 pts with known BRAF status, 44.3% (n=356) had BRAF V600E mutation and 55.7% (n=447) were BRAF wildtype. Pts with BRAF V600E mutation had OS of 18.9 months vs. 33.2 months for pts with wild type BRAF (HR 1.52, 95% CI: 1.25-1.86, p<0.001). Pts older than 50 had a lower median OS vs. those who were ≤50 at 21.4 months vs. 38.7 months (HR 1.66, 95% CI: 1.33-2.07, p<0.001). When comparing MSH2/MSH6 mutations to MLH1/PMS2, a trend towards improved OS was seen with median survival of 35.2 months vs. 22.7 months, respectively (HR 0.79, 95% CI: 0.61-1.02, p=0.067). On multivariate analysis, BRAF mutation and older age continued to be associated with differences in survival, while KRAS mutation and specific MMR gene loss did not. Conclusions: BRAF V600E mutation and age greater than 50 are associated with decreased survival for pts with MMR-D mCRC. KRAS mutations and specific MMR alterations are not associated with differences in survival.
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
Sideras, Kostandinos , Ginos, Brenda, Tenglin, Richard C., Liu, Heshan , Chen, Beiyun, Tan, Winston , Gross, Gerald G, Mowat, Rex B., Dueck, Amylou C. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Hillman, David W. , Giridhar, Karthik, Ginos, Brenda F, Dueck, A. C. , Sideras, Kostandinos , Giridhar, Karthik V. , Gross, Gerald G.

Mayo Clinic

The Oncologist | January 13, 2022 | Volume: 27 | Issue: 5 | Pages: 338-e368

10.1093/oncolo/oyab065 | PMID 35445723 Get It

Abstract Background Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized to exhibit less cardiotoxicity, mainly due to lack of iron binding. We conducted a randomized phase II study to evaluate the efficacy and safety of 2 dosing schedules of pixantrone in patients with refractory HER2-negative MBC. Methods Intravenous pixantrone was administered at 180 mg/m2 every 3 weeks (group A) versus 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B). Primary endpoint was objective response rate (ORR) and secondary endpoints included progression-free survival (PFS), median 6-month PFS, overall survival (OS), safety, quality of life, and serial assessment of circulating tumor cells. A 20% ORR was targeted as sufficient for further testing of pixantrone in this patient population. Results Forty-five patients were evaluable, with 2 confirmed partial responses in group A and 1 in group B. The trial was terminated due to insufficient activity. Overall median PFS and OS were 2.8 (95% confidence interval [CI]: 2.0-4.1) and 16.8 (95% CI: 8.9-21.6) months, respectively. Notable overall grade 3-4 adverse events were the following: neutrophil count decrease (62%), fatigue (16%), and decrease in ejection fraction (EF) (4%). Conclusion Pixantrone has insufficient activity in the second- and third-line MBC setting. It appears, however, to have limited cardiotoxicity. (ClinicalTrials.gov ID: NCT01086605).
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study
Domenighetti, Cloé , Sugier, Pierre‐Emmanuel, Sreelatha, Ashwin Ashok Kumar, Schulte, Claudia , Grover, Sandeep , Mohamed, Océane, Portugal, Berta, May, Patrick , Bobbili, Dheeraj Reddy , Radivojkov‐Blagojevic, Milena, Lichtner, Peter, Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor, Mellick, George D., Zimprich, Alexander, Pirker, Walter, Rogaeva, Ekaterina, Lang, Anthony E., Koks, Sulev, Taba, Pille, Lesage, Suzanne, Brice, Alexis, Chartier‐Harlin, Marie‐Christine, Brockmann, Kathrin , Deutschländer, Angela B., Hadjigeorgiou, Georges M., Dardiotis, Efthimos, Stefanis, Leonidas, Simitsi, Athina Maria, Petrucci, Simona, Duga, Stefano, Straniero, Letizia, Zecchinelli, Anna, Pezzoli, Gianni, Brighina, Laura, Ferrarese, Carlo, Annesi, Grazia, Quattrone, Andrea, Gagliardi, Monica, Matsuo, Hirotaka, Kawamura, Yusuke, Hattori, Nobutaka, Nishioka, Kenya, Kim, Yun Joong, Kolber, Pierre, Warrenburg, Bart P.C. van de, Bloem, Bastiaan R., Aasly, Jan, Toft, Mathias , Pihlstrøm, Lasse, Guedes, Leonor Correia, Ferreira, Joaquim J., Bardien, Soraya , Carr, Jonathan, Tolosa, Eduardo, Ezquerra, Mario , Pastor, Pau, Diez‐Fairen, Monica, Wirdefeldt, Karin, Pedersen, Nancy L., Ran, Caroline, Belin, Andrea C., Puschmann, Andreas, Hellberg, Clara, Clarke, Carl E., Morrison, Karen E., Krainc, Dimitri, Burbulla, Lena F., Farrer, Matt J., Krüger, Rejko, Gasser, Thomas, Sharma, Manu , Elbaz, Alexis , Gasser, Thomas , Hattori, Nobutaka , Chartier‐Harlin, Marie‐Christine , Puschmann, Andreas , Guedes, Leonor Correia , Zimprich, Alexander , Clarke, Carl E , Mellick, George D. , Morrison, Karen , Krüger, Rejko , Ferrarese, Carlo , Kim, Yun Joong , Pezzoli, Gianni , Pástor, Pau , Ferreira, Joaquim J. , Portugal, Berta , Straniero, Letizia , Quattrone, Andrea , Matsuo, Hirotaka , Kawamura, Yusuke , Ran, Caroline , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Chung, Sun Ju , Toft, Mathias , Bardien, Soraya , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Schulte, Claudia , Grover, Sandeep , May, Patrick , Ferreira, Joaquim J , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel, Sreelatha, Ashwin Ashok Kumar, Mohamed, Océane, Radivojkov‐Blagojevic, Milena, Lichtner, Peter, Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor, Pirker, Walter, Rogaeva, Ekaterina, Lang, Anthony E., Taba, Pille, Lesage, Suzanne, Brice, Alexis, Deutschländer, Angela B., Hadjigeorgiou, Georges M., Dardiotis, Efthimos, Stefanis, Leonidas, Simitsi, Athina Maria, Petrucci, Simona, Duga, Stefano, Zecchinelli, Anna, Brighina, Laura, Annesi, Grazia, Gagliardi, Monica, Matsuo, Hirotaka, Kawamura, Yusuke, Hattori, Nobutaka, Nishioka, Kenya, Kim, Yun Joong, Kolber, Pierre, Warrenburg, Bart P.C. van de, Bloem, Bastiaan R., Aasly, Jan, Pihlstrøm, Lasse, Guedes, Leonor Correia, Ferreira, Joaquim J., Carr, Jonathan, Tolosa, Eduardo, Diez‐Fairen, Monica, Wirdefeldt, Karin , Pedersen, Nancy L., Ran, Caroline, Belin, Andrea C., Hellberg, Clara, Clarke, Carl E., Morrison, Karen E., Krainc, Dimitri, Burbulla, Lena F., Farrer, Matt J.

Mayo Clinic

Movement Disorders | January 8, 2022 | Volume: 37 | Issue: 4 | Pages: 857-864

10.1002/mds.28902 | PMID 34997937 Get It

Abstract Background Previous prospective studies highlighted dairy intake as a risk factor for Parkinson's disease (PD), particularly in men. It is unclear whether this association is causal or explained by reverse causation or confounding. Objective The aim is to examine the association between genetically predicted dairy intake and PD using two‐sample Mendelian randomization (MR). Methods We genotyped a well‐established instrumental variable for dairy intake located in the lactase gene (rs4988235) within the Courage‐PD consortium (23 studies; 9823 patients and 8376 controls of European ancestry). Results Based on a dominant model, there was an association between genetic predisposition toward higher dairy intake and PD (odds ratio [OR] per one serving per day = 1.70, 95% confidence interval = 1.12–2.60, P = 0.013) that was restricted to men (OR = 2.50 [1.37–4.56], P = 0.003; P ‐difference with women = 0.029). Conclusions Using MR, our findings provide further support for a causal relationship between dairy intake and higher PD risk, not biased by confounding or reverse causation. Further studies are needed to elucidate the underlying mechanisms. © 2022 International Parkinson and Movement Disorder Society
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
Kocarnik, Jonathan , Compton, Kelly, Dean, Frances , Fu, Weijia , Gaw, Brian, Harvey, James , Henrikson, Hannah , Lu, Dan , Pennini, Alyssa, Xu, Rixing, Ababneh, Emad , Abbasi‐Kangevari, Mohsen , Abbastabar, Hedayat , Abd‐Elsalam, Sherief , Abedi, Aidin , Abidi, Hassan , Abolhassani, Hassan , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Aghaali, Mohammad , Ahmad, Tauseef , Rashid, Tarik A. , Salih, Yusra Ahmed , Aklilu, Addis , Akram, Tayyaba , Akunna, Chisom Joyqueenet , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem , Almasri, Nihad A. , Al‐Maweri, Sadeq Ali , Almustanyir, Sami , Alonso, Nivaldo , Alvis‐Guzmán, Nelson , Amu, Hubert , Ansari, Fereshteh, Antwi, Maxwell Hubert , Anvari, Davood , Anyasodor, Anayochukwu Edward , Aqeel, Muhammad , Arabloo, Jalal , Aremu, Olatunde , Ariffin, Hany , Aripov, Timur , Arshad, Muhammad , Artaman, Al, Arulappan, Judie , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Atorkey, Prince , Ausloos, Marcel , Awedew, Atalel Fentahun , Quintanilla, Beatriz Paulina Ayala , Ayenew, Temesgen , Azab, Mohammed A. , Azadnajafabad, Sina , Jafari, Amirhossein Azari , Azarian, Ghasem , Badiye, Ashish , Bahadory, Saeed , Baig, Atif Amin , Baker, Jennifer L. , Balakrishnan, Senthilkumar , Bärnighausen, Till , Barone‐Adesi, Francesco , Barrow, Amadou , Belgaumi, Uzma , Bezabhe, Woldesellassie, Bezabih, Yihienew Mequanint , Bhagat, Devidas S. , Bhagavathula, Akshaya Srikanth , Bhardwaj, Nikha , Bhaskar, Sonu , Bhojaraja, Vijayalakshmi S, Bibi, Sadia , Bijani, Ali , Bisignano, Catherine, Bolarinwa, Obasanjo Afolabi , Bolla, Srinivasa Rao , Braithwaite, Dejana , Brar, Amanpreet , Brenner, Hermann , Bustamante-Teixeira, Maria Teresa , Butt, Nadeem Shafique , Butt, Zahid A , Santos, Florentino Luciano Caetano dos , Cao, Yin , Carreras, Giulia , Catalá-López, Ferrán , Cembranel, Francieli , Cerin, Ester , Cernigliaro, Achille , Chakinala, Raja Chandra , Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chimed‐Ochir, Odgerel , Cho, Daniel , Chu, Dinh‐Toi , Conde, João , Cortés, Sandra , Cortesi, Paolo Angelo, Costa, Vera Marisa , Cunha, Amanda Ramos da , Dadras, Omid , Dagnew, Amare Belachew , Dandona, Lalit , Dandona, Rakhi , Hoz, Fernando de la , Dhamnetiya, Deepak , Dhimal, Mandira Lamichhane , Díaz, Daniel , Djalalinia, Shirin , Doaei, Saeid , Dorostkar, Fariba, Driscoll, Tim , Ebrahimi, Hedyeh , Eftekharzadeh, Sahar , Tantawi, Maha El , El‐Abid, Hassan , Elbarazi, Iffat , Elhabashy, Hala Rashad , Elhadi, Muhammed , Eshrati, Babak, Esmaeilzadeh, Firooz , Etemadi, Arash , Ezzikouri, Sayeh , Faisaluddin, Mohammed, Fares, Jawad , Farzadfar, Farshad , Feroze, Abdullah , Desideri, Lorenzo Ferro , Fischer, Florian , Fisher, James L. , Fukumoto, Takeshi , Gad, Mohamed M. , Fonseca, Mariana Gaspar, Obsa, Abera Getachew, Ghafourifard, Mansour , Ghashghaee, Ahmad , Ghith, Nermin , Gholamalizadeh, Maryam , Gilani, Syed Amir , Gizaw, Abraham Tamirat , Glasbey, James , Golechha, Mahaveer , Goleij, Pouya , Gopalani, Sameer Vali , Gorini, Giuseppe , Goudarzi, Houman , Gubari, Mohammed Ibrahim Mohialdeen , Guerra, Maximiliano Ribeiro, Guha, Avirup , Gunasekera, Sanjeeva , Gupta, Bhawna , Gupta, Vivek , Gutiérrez, Reyna Alma, Hafezi‐Nejad, Nima , Haider, Mohammad Rifat , Hameed, Sajid , Hanif, Asif , Haque, Shafiul , Harlianto, Netanja I. , Hasaballah, Ahmed I , Hay, Simon I , Heidari, Golnaz , Herrera-Serna, Brenda Yuliana , Herţeliu, Claudiu , Hezam, Kamal , Hossain, Mohammad Bellal , Hosseini, Mohammad‐Salar , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela , Househ, Mowafa , Hsaïri, Mohamed, Huang, Junjie , Hugo, Fernando Neves , Hussain, Rabia , Hussein, Nawfal R , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ida, Fidelia , Ikuta, Kevin S , Ilić, Irena , Irham, Lalu Muhammad , Islam, Jessica Y. , Islam, Sheikh Mohammed Shariful , Ismail, Nahlah Elkudssiah , Isola, Gaetano , Iwagami, Masao , Jacob, Louis , Jain, Vardhmaan , Jakovljević, Mihajlo, Javaheri, Tahereh , Jayaram, Shubha, Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kalankesh, Leila R , Kalhor, Rohollah , Kalkonde, Yogeshwar , Kamath, Ashwin , Al-Salihi, Nawzad Kameran, Kandel, Himal , Kapoor, Neeti , Kasa, Ayele Semachew , Keshavarz, Pedram , Keykhaei, Mohammad , Khader, Yousef , Khalilov, Rovshan , Khan, Maseer , Khan, Md Nuruzzaman , Khan, Moien AB , Khang, Young-Ho, Khater, Amir M, Kısa, Adnan , Kısa, Sezer , Kopec, Jacek A , Koteeswaran, Rajasekaran , Koul, Parvaiz A , Laxminarayana, Sindhura Lakshmi Koulmane , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, G Anil , Kurmi, Om , Kutluk, Tezer, Lami, Faris Hasan, Lee, Yo Han , Leigh, James , Leong, Elvynna , Li, Ming‐Chieh , Liu, Xuefeng , Loureiro, Joana A. , Lunevičius, Raimundas , Razek, Muhammed Magdy Abd El, Majeed, Azeem , Makki, Alaa, Male, Shilpa, Malik, Ahmad Azam , Martini, Santi , Masoumi, Seyedeh Zahra , Mehrotra, Ravi , Mendoza, Walter, Mengesha, Endalkachew Worku , Mesregah, Mohamed Kamal , Jonasson, Junmei Miao , Miazgowski, Bartosz , Miazgowski, Tomasz , Michałek, Irmina Maria , Miller, Ted R. , Mirzaei, Hamid Reza , Misra, Sanjeev , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Mokhtar , Mohammadi, Seyyede Momeneh, Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Moka, Nagabhishek , Mokdad, Ali H. , Molokhia, Mariam , Monasta, Lorenzo , Moosavi, Mohammad Amin , Moradi, Yousef , Moraga, Paula , Morgado-da-Costa, Joana, Mubarik, Sumaira , Mwanri, Lillian , Nagarajan, Ahamarshan Jayaraman , Nagata, Chie , Naimzada, Mukhammad David , Nangia, Vinay, Naqvi, Atta Abbas , Swamy, Sreenivas Narasimha, Negoi, Ionuţ , Negru, Șerban , Kandel, Sandhya Neupane , Nguyen, Cuong Tat , Niazi, Robina Khan, Nnaji, Chukwudi A , Noor, Nurulamin M , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olakunde, Babayemi O. , Omar, Emad, Bali, Ahmed Omar , Omonisi, Abidemi , Ong, Sokking, Onwujekwe, Obinna , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Pakshir, Keyvan , Pană, Adrian , Panagiotakos, Demosthenes B. , Panda‐Jonas, Songhomitra, Park, Eun‐Cheol , Park, Eun‐Kee , Kan, Fatemeh Pashazadeh , Patel, Harsh K. , Patel, Jenil , Pati, Siddhartha , Paudel, Uttam , Pereira, David M. , Pereira, Renato B. , Perianayagam, Arokiasamy , Pillay, Julian David , Pirouzpanah, Saeed , Podder, Indrashis , Postma, Maarten J. , Prashant, Akila , Preoțescu, Liliana , Rabiee, Navid , Radfar, Amir , Radhakrishnan, Raghu , Radhakrishnan, Venkatraman , Rahim, Fakher , Rahimzadeh, Shadi , Rahman, Mosiur , Rahman, Muhammad Aziz , Rajai, Nazanin , Rajesh, Aashish , Ram, Pradhum , Ramezanzadeh, Kiana, Ranabhat, Kamal , Rao, Chythra R , Rao, Sowmya J, Rawassizadeh, Reza , Razeghinia, Mohammad Sadegh , Rezapour, Aziz, Buendía, Jefferson Antonio , Rohloff, Peter , Rwegerera, Godfrey Mutashambara , Manjula, S, Saddik, Basema , Saeed, Umar , Sahoo, Harihar , Salehi, Sana , Salem, Marwa Rashad , Samaei, Mehrnoosh, Samy, Abdallah M , Sanabria, Juan , Sankararaman, Senthilkumar , Santric-Milicevic, Milena M , Sardiwalla, Yaeesh , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Šekerija, Mario , Seylani, Allen, Shafaat, Omid , Shaikh, Masood Ali , Shannawaz, Mohammed , Sheikhbahaei, Sara , Shetty, Adithi , Shetty, Jeevan K. , Shetty, Pavanchand H, Shirkoohi, Reza , Shivarov, Velizar , Malleshappa, Sudeep K Siddappa , Silva, Diego Augusto Santos , Sintayehu, Yitagesu , Skryabin, Valentin Yurievich , Soeberg, Matthew, Sofi‐Mahmudi, Ahmad , Steiropoulos, Paschalis , Straif, Kurt, Subedi, Ranjeeta , Sultana, Saima , Szerencsés, Viktória , Tabuchi, Takahiro , Tadbiri, Hooman , Takahashi, Ken , Tan, Ker‐Kan , Tat, Vivian Y, Tedla, Bemnet , Tefera, Yonas Getaye , Temsah, Mohamad‐Hani , Tesfay, Fisaha Haile , Tessema, Gizachew Assefa , Thavamani, Aravind , Chandrasekar, Viveksandeep Thoguluva , Touvier, Mathilde , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Mai Thi Ngoc , Tripathy, Jaya Prasad , Tusa, Biruk Shalmeno , Ullah, Irfan , Ullah, Saif , Umapathi, Krishna Kishore , Vaezi, Maryam, Tahbaz, Sahel Valadan , Velazquez, Diana Zuleika , Violante, Francesco Saverio , Volovici, Victor , Vu, Giang Thu , Waheed, Yasir , Ward, Paul , Wen, Yi Feng , Westerman, Ronny, Yadav, Lalit , Jabbari, Seyed Hossein Yahyazadeh, Yang, Lin , Yazie, Taklo Simeneh , Yeshaw, Yigizie , Younis, Mustafa Z , Yousefi, Zabihollah , Yunusa, Ismaeel , Zadnik, Vesna , Zare, Fariba , Застрожин, Михаил Сергеевич , Zastrozhina, Anasthasia, Zhang, Jianrong , Zhong, Chenwen, Zhu, Cong , Zimmermann, Ivan Ricardo , Fitzmaurice, Christina , Murray, Christopher J L , Force, Lisa M , Ong, Sok King , Eftekhari, Aziz , Guimarães, André Luiz Sena , Kumar, Vivek , Lami, Faris , Liu, Xuefeng , Baig, Atif Amin , Thoguluva Chandrasekar, Viveksandeep, Kumar, Vivek , Cao, Yin , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Guha, Avirup , Ebrahimi, Hedyeh , Volovici, Victor , Bhagavathula, Akshaya Srikanth , Jakovljević, Mihajlo , Elhadi, Muhammed , Abdoli, Amir , Adnani, Qorinah Estiningtyas Sakilah , Afzal, Muhammad Sohail, Ahinkorah, Bright Opoku , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Sepideh , Akalu, Gizachew Taddesse , Al‐Aly, Ziyad , Ali, Saqib , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Anbesu, Etsay Woldu , Ancuceanu, Robert , Ansari‐Moghaddam, Alireza , Arab-Zozani, Morteza , Asemi, Zatollah , Aujayeb, Avinash , Azzam, Ahmed Y , Banach, Maciej , Barra, Fabio , Behzadifar, Masoud , Bezabhe, Woldesellassie M Mequanint , Bhardwaj, Pankaj , Bhattacharyya, Krittika , Biondi, Antonio , Bjørge, Tone , Bleyer, Archie , Blyuss, Oleg B. , Chaturvedi, Pankaj, Christopher, Devasahayam Jesudas , Chung, Michael T. , Cortesi, Paolo Angelo , Belachew, Amare , Dahlawi, Saad M A , Dai, Xiaochen , Darwesh, Aso Mohammad , Neves, José das , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Dhimal, Meghnath , Dianatinasab, Mostafa , Do, Huyen Phuc , Doaei, Saeid , Figueiredo, Francisco Winter dos Santos , El-Jaafary, Shaimaa I , Eskandarieh, Sharareh , Faraon, Emerito Jose A , Ferrero, Simone , Filip, Irina , Foroutan, Masoud , Gaál, Péter , Gadanya, Muktar A , Gallus, Silvano , Gomez, Ricardo Santiago , Grosso, Giuseppe , Gupta, Veer Bala , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hamadeh, Randah R , Hamidi, Samer , Haro, Josep María , Hassanipour, Soheil , Hay, Roderick J. , Hayat, Khezar , Heidari, Mohammad , Holla, Ramesh , Hossain, Md Mahbub , Hostiuc, Sorin , Iavicoli, Ivo , Ilesanmi, Olayinka Stephen , Ilić, Milena , Islam, Rakibul M. , Jazayeri, Seyed Behzad , Kabir, Ali , Kahrizi, Danial , Kaliyadan, Feroze , Karch, André , Katikireddi, Srinivasa Vittal , Kauppila, Joonas H. , Kavetskyy, Taras , Kebede, Sewnet Adem , Khan, Gulfaraz , Khang, Young-Ho, Khayamzadeh, Maryam , Kim, Gyu Ri , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Kumar, Narinder , Kumar, Nithin , Vecchia, Carlo La , Landires, Iván , Lauriola, Paolo , Lee, Sang Hyuck , Lee, Shaun Wen Huey , Lee, Wei‐Chen , Li, Jiarui , Mansournia, Mohammad Alì , Mathur, Prashant , McKee, Martin , Menezes, Ritesh G. , Meštrović, Tomislav , Mirzaei, Hamed , Moni, Mohammad Ali , Morrison, Shane D. , Mosapour, Abbas , Nagaraju, Shankar Prasad , Ndejjo, Rawlance , Nduaguba, Sabina O. , Nguyen, Huong Lan Thi , Núñez-Samudio, Virginia , Оchir, Chimedsuren , Odukoya, Oluwakemi Ololade , Ong, Sokking, Orru, Hans , Otstavnov, Nikita , Owolabi, Mayowa , Padubidri, Jagadish Rao , Pardhan, Shahina , Pattanshetty, Sanjay M. , Pishgar, Farhad , Pourjafar, Hadi , Rabiee, Mohammad , Rafiee, Ata , Rahmani, Amir Masoud , Rakovac, Ivo , Ranasinghe, Priyanga Diloshini , Renzaho, André M. N. , Rezaei, Negar , Rezaei, Nima , Roberts, Thomas J. , Romoli, Michele , Ronfani, Luca , Roshandel, Gholamreza , Sabour, Siamak , Sahebkar, Amirhossein , Salimzadeh, Hamideh , Şaylan, Mete , Schneider, Ione Jayce Ceola , Shaghaghi, Zahra , Shamsoddin, Erfan , Sharma, Rajesh , Sheikh, Aziz , Shibuya, Kenji , Shivakumar, K. M. , Siabani, Soraya , Singh, Jasvinder A. , Skryabina, Anna Aleksandrovna , Sotoudeh, Houman , Sufiyan, Mu’awiyyah Babale , Sultan, Iyad Yasin , Sur, Daniel Genel , Szócska, Miklós , Tabarés‐Seisdedos, Rafael , Taherkhani, Amir , Talaat, Iman Mamdouh , Tehrani‐Banihashemi, Arash , Thapar, Rekha , Thomas, Nihal , Tohidinik, Hamid Reza , Tran, Bach Xuan , Tran, Khanh Bao , Unnikrishnan, Bhaskaran , Upadhyay, Era , Vacante, Marco , Vaezi, Maryam, Veroux, Massimiliano , Vlassov, Vasily , Vo, Bay, Wamai, Richard G. , Winkler, Andrea Sylvia , Yaya, Sanni , Yonemoto, Naohiro , Yu, Chuanhua , Yüce, Deniz , Zhou, Linghui , Ziapour, Arash , Olagunju, Andrew T , Shivakumar, KM , Baig, Atif Amin , Alahdab, Fares , Asghari-Jafarabadi, Mohammad , Rahim, Fakher

Mayo Clinic

JAMA Oncology | December 30, 2021 | Volume: 8 | Issue: 3 | Pages: 420

10.1001/jamaoncol.2021.6987 | PMID 34967848 Get It

Ventricular Arrhythmias Among Patients With Advanced Heart Failure: A Population‐Based Study
Tan, Nicholas Y. , Roger, Véronique L. , Killian, Jill M. , Cha, Yong‐Mei , Noseworthy, Peter A. , Dunlay, Shannon M. , Noseworthy, Peter A , Dunlay, Shannon

Mayo Clinic

Journal of the American Heart Association | December 22, 2021 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/jaha.121.023377 | PMID 34935408 Get It

Background The epidemiology of ventricular arrhythmias (VAs) in patients with advanced heart failure (HF) is not well defined. Methods and Results Residents of Olmsted County, Minnesota, with advanced HF from 2007 to 2017 were identified using the 2018 European Society of Cardiology criteria. Billing codes were used to capture VAs; severe VAs requiring emergency care were defined as events associated with emergency department visits or hospitalizations. The cumulative incidence of VAs postadvanced HF was estimated with the Kaplan–Meier method. Multivariable Cox analyses were used to determine the following: (1) Predictors of severe VAs postadvanced HF; and (2) Impact of severe VAs on mortality. Of 936 patients with advanced HF, 261 (27.9%) had a history of VA. The 1‐year cumulative incidence of severe VAs postadvanced HF was 5.4%. Prior VAs (hazard ratio [HR] 2.22 [95% CI, 1.26–3.89], P =0.006) and left ventricular ejection fraction <40% (HR, 3.79 [95% CI, 1.72–8.39], P <0.001) were independently associated with increased severe VA risk postadvanced HF. New‐onset severe VAs were associated with increased mortality (HR, 4.41 [95% CI, 2.80–6.94]; P <0.001), whereas severe VAs in patients with prior VAs had no significant association with mortality risk (HR, 1.08 [95% CI, 0.65–1.78]; P =0.77). Severe VAs were associated with increased mortality in patients without implantable cardioverter defibrillators (HR, 4.89 [95% CI, 2.89–8.26]; P <0.001), but not in patients with implantable cardioverter defibrillators (HR, 1.42 [95% CI, 0.92–2.19]; P =0.11). Conclusions Patients with left ventricular ejection fraction <40% and prior VAs have increased risk of severe VA postadvanced HF. New‐onset severe VAs or severe VAs without implantable cardioverter defibrillators postadvanced HF are associated with increased mortality.